| BIOPHARMACEUTICAL-COMPANIES |
BIOPHARMACEUTICAL-COMPANIES |
92%
|
We believe biopharmaceutical companies are increasingly recognizing and appreciating the scientific and financial benefits of using our platform at scale. |
| CUSTOMER |
CUSTOMER |
92%
|
For the three months ended March 31, 2026, two customers accounted for 22 % and 18 % of total revenue, respectively. |
| CUSTOMERS-WITH-AN-ACV-OF-AT-LEAST-100-000 |
CUSTOMERS-WITH-AN-ACV-OF-AT-LEAST-100-000 |
92%
|
Our year-over-year customer retention rate for our customers with an ACV of at least $100,000 was 95% and was 92% or higher for each of the previous 10 fiscal years. |
| CUSTOMERS-WITH-AN-ACV-OF-AT-LEAST-500-000 |
CUSTOMERS-WITH-AN-ACV-OF-AT-LEAST-500-000 |
92%
|
Our customer retention rate for our customers with an ACV of at least $500,000 was 100%, 98%, 100% for the years ended December 31, 2024, 2023, and 2022, respectively. |
| SOFTWARE-CUSTOMERS |
SOFTWARE-CUSTOMERS |
92%
|
This is demonstrated by the length of our key relationships, with the average tenure of our 10 largest software customers in 2024 being nearly 21 years. |
| CDNS |
Cadence Design Systems, Inc. |
85%
|
g technology. Our ability to remain competitive will largely depend on our ability to continue to improve our computational platform and demonstrate success in our drug discovery efforts. Our softwar… |
| CDNS |
Cadence Design Systems, Inc. |
85%
|
Reciprocal relationship from CDNS graph: Reciprocal relationship from SDGR graph: Reciprocal relationship from CDNS graph: Reciprocal relationship from SDGR graph: g technology. Our ability to remain… |
| SLP |
Simulations Plus, Inc. |
85%
|
Reciprocal relationship from SLP graph: Reciprocal relationship from SDGR graph: Reciprocal relationship from SLP graph: Reciprocal relationship from SDGR graph: g technology. Our ability to remain c… |
| SLP |
Simulations Plus, Inc. |
85%
|
g technology. Our ability to remain competitive will largely depend on our ability to continue to improve our computational platform and demonstrate success in our drug discovery efforts. Our softwar… |
| APRE |
Aprea Therapeutics, Inc. |
72%
|
g technology. Our ability to remain competitive will largely depend on our ability to continue to improve our computational platform and demonstrate success in our drug discovery efforts. Our softwar… |
| APRE |
Aprea Therapeutics, Inc. |
72%
|
Reciprocal relationship from APRE graph: Reciprocal relationship from SDGR graph: Reciprocal relationship from APRE graph: Reciprocal relationship from SDGR graph: g technology. Our ability to remain… |
| GPCR |
Structure Therapeutics Inc. |
72%
|
performance-based vesting conditions are considered probable as of that date. F-30 Table of Contents (11) . The Company has no obligation to fund Nimbus' losses in excess of its investment. gain or l… |
| GPCR |
Structure Therapeutics Inc. |
72%
|
Reciprocal relationship from GPCR graph: Reciprocal relationship from SDGR graph: performance-based vesting conditions are considered probable as of that date. F-30 Table of Contents (11) . The Compa… |
| LLY |
Eli Lilly and Company |
72%
|
performance-based vesting conditions are considered probable as of that date. F-30 Table of Contents (11) . The Company has no obligation to fund Nimbus' losses in excess of its investment. gain or l… |
| LLY |
Eli Lilly and Company |
72%
|
Reciprocal relationship from LLY graph: Reciprocal relationship from SDGR graph: performance-based vesting conditions are considered probable as of that date. F-30 Table of Contents (11) . The Compan… |
| NVSEF |
Novartis AG |
72%
|
e software solution directly on their own in-house hardware and use it for a specified term, or (ii) a subscription that allows our customers to access our cloud-based software solution on their own … |
| NVSEF |
Novartis AG |
72%
|
Reciprocal relationship from NVSEF graph: Reciprocal relationship from SDGR graph: e software solution directly on their own in-house hardware and use it for a specified term, or (ii) a subscription … |
| RXRX |
Recursion Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from RXRX graph: Reciprocal relationship from SDGR graph: g technology. Our ability to remain competitive will largely depend on our ability to continue to improve our computa… |
| RXRX |
Recursion Pharmaceuticals, Inc. |
72%
|
g technology. Our ability to remain competitive will largely depend on our ability to continue to improve our computational platform and demonstrate success in our drug discovery efforts. Our softwar… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from SDGR graph: collaborate with a number of materials science companies to help accelerate the discovery and development of new mat… |
| SNYNF |
Sanofi |
72%
|
collaborate with a number of materials science companies to help accelerate the discovery and development of new materials. For example, in 2023, we entered into a research collaboration with Coperni… |
| ABCELLERA-INDUCTIVE-BIO-INC-CHEMAXON-PERKINELMER |
ABCELLERA-INDUCTIVE-BIO-INC-CHEMAXON-PERKINELMER |
62%
|
chnology. Our ability to remain competitive will largely depend on our ability to continue to improve our computational platform and demonstrate success in our drug discovery efforts. Our software so… |
| AJAX-THERAPEUTICS-INC-BMS-BRIGHT-ANGEL-THERAPEUT |
AJAX-THERAPEUTICS-INC-BMS-BRIGHT-ANGEL-THERAPEUT |
62%
|
will be eligible to receive additional equity upon the successful completion of certain technical milestones. In 2023, we also entered into a research collaboration with Copernic Catalysts, Inc. to h… |
| COPERNIC-CATALYSTS-INC |
COPERNIC-CATALYSTS-INC |
62%
|
will be eligible to receive additional equity upon the successful completion of certain technical milestones. In 2023, we also entered into a research collaboration with Copernic Catalysts, Inc. to h… |
| EMPLOYEE-RESOURCE-GROUP |
EMPLOYEE-RESOURCE-GROUP |
62%
|
pproval date. Only one patent applicable to an approved product is eligible for the extension, and only those claims covering the approved product, a method for using it, or a method for manufacturin… |
| LILLY-NOVARTIS-OTSUKA-PHARMACEUTICAL-CO-LTD |
LILLY-NOVARTIS-OTSUKA-PHARMACEUTICAL-CO-LTD |
62%
|
will be eligible to receive additional equity upon the successful completion of certain technical milestones. In 2023, we also entered into a research collaboration with Copernic Catalysts, Inc. to h… |
| MORPHIC-HOLDING-INC |
MORPHIC-HOLDING-INC |
62%
|
r collaborators. For example, in 2024, we received $47.6 million for the equity stake that we owned in Morphic Holding, Inc., or Morphic, one of our drug discovery collaborators and co-founded compan… |
| NIMBUS-LAKSHMI-INC |
NIMBUS-LAKSHMI-INC |
62%
|
on account of our equity investment in Nimbus, from Nimbus in connection with Takeda’s acquisition of Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus, and its TYK2 inhibitor NDI-034858 and … |
| NIMBUS-STRUCTURE-THERAPEUTICS-INC |
NIMBUS-STRUCTURE-THERAPEUTICS-INC |
62%
|
this time, we do not know, nor can we reasonably estimate, the nature, timing, or costs of the efforts that will be necessary to complete the development of any of our proprietary drug discovery prog… |
| NIMBUS-THERAPEUTICS-LLC |
NIMBUS-THERAPEUTICS-LLC |
62%
|
,393 2,407 Drug discovery 94,421 6,636 For the years ended December 31, 2024 and 2023, the Company recognized $ 53,438 and $ 64,120 of revenue, respectively, that was included in deferred revenue at … |
